News Releases :: Sutro Biopharma, Inc. (STRO)

Feb 17, 2023 4:01 pm EST

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 9, 2023 4:05 pm EST

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

Jan 4, 2023 8:00 am EST

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 21, 2022 8:00 am EST

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

Dec 20, 2022 4:05 pm EST

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

Dec 10, 2022 10:30 am EST

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Nov 23, 2022 7:00 am EST

Sutro Biopharma to Participate in Upcoming Investor Conferences

Nov 8, 2022 4:30 pm EST

Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Nov 3, 2022 9:00 am EDT

Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

Nov 2, 2022 7:00 am EDT

Sutro Biopharma to Participate in Upcoming Investor Conferences